GILD News and Press, Gilead Sciences Inc.

2024-05-19 14:00:55 ET More on pharma companies Novo Nordisk, J&J lead R&D rankings in big pharma: report Shockwave Medical: A Look Into Q1 Financials And Value To Johnson & Johnson Investors Johnson & Johnson: Buy This Bargain Before It's Gone ...

- 70% of Patients Receiving Seladelpar 10mg Achieved the Clinically Meaningful Composite Endpoint and 37% Achieved ALP Normalization at 12 Months - - Reduction in Patient-Reported Pruritus (Itching) was Rapid and Durable in Patients with Moderate to Severe Symptoms - - Pos...

2024-05-16 14:27:26 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Penny stocks to buy understandably offer many enticing attributes, not least of which is the potential for tremendous returns. Of course, the emphasis is on the word “potential. ...

2024-05-15 15:59:09 ET Gilead Sciences, Inc. (GILD) RBC Capital Markets Global Healthcare Conference May 15, 2024 10:30 AM ET Company Participants Johanna Mercier - Chief Commercial Officer Conference Call Participants Brian Abrahams - RBC Capital Markets ...

2024-05-15 08:45:36 ET Summary Pfizer has been a losing investment for several years, but stronger trading momentum is starting to appear. An easily covered and safety-minded 6% dividend yield is very attractive today. Undervaluation arguments to own shares also exist. PFE sto...

2024-05-14 16:25:24 ET Gilead Sciences, Inc. (GILD) BofA Securities 2024 Health Care Conference May 14, 2024, 02:20 PM ET Company Participants Geoff Meacham - Bank of America Securities Conference Call Participants Andrew Dickinson - Chief Financial Officer ...

– Analysis Comparing Real-World and Clinical Trial Data Show Yescarta ® Has Higher Manufacturing Success Rates and Improved T-Cell Performance, Respectively, in Second-Line vs. Third-Line+ Treatment of Large B-cell Lymphoma – – Encore Oral Present...

2024-05-14 08:10:00 ET Summary Portfolio changes in April focus on BDCs, aiming to increase dividend income by at least $100 each month. Dividend income hit a new all-time record for April of $736, basically flat Y/Y and up 12% sequentially. Gifted Working Time 2024: Around 85...

2024-05-13 07:58:54 ET Merck ( NYSE: MRK ) has discontinued the vibostolimab and pembrolizumab coformulation arm of a late-stage skin cancer trial .... Read the full article on Seeking Alpha For further details see: Merck discontinues testing of experimental skin...

2024-05-09 17:13:21 ET More on Gilead Sciences, Arcellx Gilead Sciences, Inc. (GILD) Q1 2024 Earnings Call Transcript Gilead Sciences, Inc. 2024 Q1 - Results - Earnings Call Presentation Gilead Q1 Earnings Preview: Most Gains Wiped Out - Cause For Concern? Gi...